Fig. 3From: Oncogenic alterations in advanced NSCLC: a molecular super-highwayEMA timeline of drug approvals. Since 2003, there has been a rapid acceleration of drug development and approvals for molecular targeted therapies in NSCLC. Today, both kinase inhibitors and antibody–drug conjugates are approvedBack to article page